Outcomes of stereotactic radiosurgery for large vestibular schwannomas: a systematic review and meta-analysis.
Koos IV
acoustic neuroma
large vestibular schwannoma
radiosurgery
stereotactic radiosurgery
Journal
Neuro-oncology practice
ISSN: 2054-2577
Titre abrégé: Neurooncol Pract
Pays: England
ID NLM: 101640528
Informations de publication
Date de publication:
Aug 2021
Aug 2021
Historique:
entrez:
19
7
2021
pubmed:
20
7
2021
medline:
20
7
2021
Statut:
epublish
Résumé
Large vestibular schwannomas (VS) pose a treatment challenge for both microsurgery (MS) and stereotactic radiosurgery (SRS). Technical developments have allowed for safer irradiation of large tumors. It remains unclear if SRS can achieve appropriate tumor control and acceptable cranial nerve toxicities. In this study, we assess outcomes of irradiation for large VS. PubMed MEDLINE, EMBASE, Web of Science, and Cochrane were searched for all the studies assessing SRS outcome in large VS. Primary endpoints included clinical and radiographic tumor control, need for salvage surgery, serviceable hearing, cranial nerve V and VII impairment, presence of hydrocephalus requiring shunting, and presence of vertigo/dizziness. Twenty-two studies were identified that met selection criteria for analysis from an initial pool of 1272 reports. They were evaluated according to treatment protocol: 1) single-dose SRS (13 studies, 483 patients), 2) combination of MS and SRS (7 studies, 182 patients), and 3) fractionated SRS (3 studies, 82 patients). Tumor control was achieved in 89%, 94%, and 91% of patients, respectively. Odds ratios (ORs) of post- over pretreatment serviceable hearing were 0.42 ( The management of large VS remains challenging. All treatment modalities resulted in high tumor control rates and worsening of pretreatment hearing. None, however, caused significant facial nerve impairment, suggesting that management strategies incorporating focal irradiation can be successful.
Sections du résumé
BACKGROUND
BACKGROUND
Large vestibular schwannomas (VS) pose a treatment challenge for both microsurgery (MS) and stereotactic radiosurgery (SRS). Technical developments have allowed for safer irradiation of large tumors. It remains unclear if SRS can achieve appropriate tumor control and acceptable cranial nerve toxicities. In this study, we assess outcomes of irradiation for large VS.
METHODS
METHODS
PubMed MEDLINE, EMBASE, Web of Science, and Cochrane were searched for all the studies assessing SRS outcome in large VS. Primary endpoints included clinical and radiographic tumor control, need for salvage surgery, serviceable hearing, cranial nerve V and VII impairment, presence of hydrocephalus requiring shunting, and presence of vertigo/dizziness.
RESULTS
RESULTS
Twenty-two studies were identified that met selection criteria for analysis from an initial pool of 1272 reports. They were evaluated according to treatment protocol: 1) single-dose SRS (13 studies, 483 patients), 2) combination of MS and SRS (7 studies, 182 patients), and 3) fractionated SRS (3 studies, 82 patients). Tumor control was achieved in 89%, 94%, and 91% of patients, respectively. Odds ratios (ORs) of post- over pretreatment serviceable hearing were 0.42 (
CONCLUSIONS
CONCLUSIONS
The management of large VS remains challenging. All treatment modalities resulted in high tumor control rates and worsening of pretreatment hearing. None, however, caused significant facial nerve impairment, suggesting that management strategies incorporating focal irradiation can be successful.
Identifiants
pubmed: 34277019
doi: 10.1093/nop/npab011
pii: npab011
pmc: PMC8278356
doi:
Types de publication
Journal Article
Review
Langues
eng
Pagination
405-416Subventions
Organisme : NCATS NIH HHS
ID : UL1 TR002384
Pays : United States
Informations de copyright
© The Author(s) 2021. Published by Oxford University Press on behalf of the Society for Neuro-Oncology and the European Association of Neuro-Oncology. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com.
Références
J Neurosurg. 2012 Dec;117 Suppl:69-77
pubmed: 23205792
Neuro Oncol. 2006 Jan;8(1):1-11
pubmed: 16443943
J Neurosurg. 2018 May;128(5):1380-1387
pubmed: 28707997
Br J Radiol. 1999 Dec;72(864):1202-7
pubmed: 10703478
J Neurosurg. 2013 Aug;119(2):463-71
pubmed: 23706053
Prog Neurol Surg. 2008;21:192-199
pubmed: 18810219
World Neurosurg. 2019 Jul;127:e599-e608
pubmed: 30930324
Stereotact Funct Neurosurg. 2017;95(3):166-173
pubmed: 28531896
Neurosurgery. 1998 Sep;43(3):475-81; discussion 481-3
pubmed: 9733302
J Neurosurg. 2005 Jan;102 Suppl:87-96
pubmed: 15662787
Stereotact Funct Neurosurg. 2016;94(4):216-224
pubmed: 27513938
J Neurosurg. 2014 Dec;121 Suppl:123-42
pubmed: 25434946
Can J Neurol Sci. 2013 May;40(3):342-7
pubmed: 23603169
J Neurosurg. 2011 Nov;115(5):885-93
pubmed: 21838503
Otolaryngol Head Neck Surg. 2017 Jul;157(1):7-15
pubmed: 28441508
J Neurosurg. 2011 Nov;115(5):896-7
pubmed: 21838507
J Neurooncol. 2019 Nov;145(2):329-337
pubmed: 31552587
Otolaryngol Head Neck Surg. 2018 Sep;159(3):535-542
pubmed: 29685084
Acta Neurochir (Wien). 2019 Jul;161(7):1457-1465
pubmed: 31127373
Otol Neurotol. 2020 Feb;41(2):e256-e261
pubmed: 31644476
J Neurosurg. 2011 Mar;114(3):801-7
pubmed: 20799863
N Engl J Med. 1998 Nov 12;339(20):1426-33
pubmed: 9811917
World Neurosurg. 2018 Jun;114:e1192-e1198
pubmed: 29614352
Head Neck Pathol. 2020 Dec;14(4):1058-1066
pubmed: 32232723
J Neurosurg. 2015 Apr;122(4):818-24
pubmed: 25594321
J Neurosurg. 2010 Dec;113 Suppl:112-21
pubmed: 21121793
Neurosurgery. 2008 Dec;63(6):1054-62; discussion 1062-3
pubmed: 19057318
World Neurosurg. 2016 Nov;95:487-501
pubmed: 27535636
Surg Neurol. 2003 Apr;59(4):283-9; discussion 289-91
pubmed: 12748011
Neuro Oncol. 2020 Jan 11;22(1):31-45
pubmed: 31504802
J Neurosurg. 2005 Jan;102 Suppl:111-3
pubmed: 15662791
Clin Neurol Neurosurg. 2020 Jun;193:105769
pubmed: 32146233
World Neurosurg. 2015 Aug;84(2):292-300
pubmed: 25790872
Neurosurg Focus. 2018 Mar;44(3):E4
pubmed: 29490553
J Clin Neurosci. 2014 Jul;21(7):1083-8
pubmed: 24513160
Int J Radiat Oncol Biol Phys. 2011 Mar 15;79(4):985-97
pubmed: 21353158
Acta Neurochir (Wien). 2017 Jul;159(7):1197-1211
pubmed: 28516364
Neuro Oncol. 2017 Apr 1;19(suppl_2):ii38-ii49
pubmed: 28380634
J Neurosurg. 2019 Sep 6;:1-7
pubmed: 31491764
Neurosurgery. 2019 Sep 1;85(3):409-414
pubmed: 30169695
Neurosurgery. 2016 Apr;78(4):521-30
pubmed: 26606668
J Neurosurg. 2012 Mar;116(3):598-604
pubmed: 22175724
Can J Neurol Sci. 2013 May;40(3):280-1
pubmed: 23603160
World Neurosurg. 2016 Sep;93:398-409
pubmed: 27368508
J Neurosurg. 2011 Nov;115(5):875-84
pubmed: 21838510
World Neurosurg. 2019 Sep;129:e303-e310
pubmed: 31132496
Prog Neurol Surg. 2008;21:79-82
pubmed: 18810202
J Neurosurg. 2011 Nov;115(5):894-5
pubmed: 21838509